
It takes a specialist like Zurex Pharma to overcome the scientific and technical barriers to improved skin antisepsis – a critical component in the prevention of Surgical Site Infections (SSIs).
Board of Directors
Frederick A. Robertson, M.D.
Chairman
Thomas V. Ressemann
Independent Director
Michael Liang, Ph.D.
Partner, Baird Capital
Robert B. Truitt
President and CEO, Ash
Access Technology
Scientific Advisory Board
Dr. Scott Anseth
Surgeon, Twin Cities Orthopedics
Dr. Charles E. Edmiston, Jr. Ph.D
Infection Prevention
Dr. Andrew Mulder
Surgeon, St. Cloud Orthopedics
Maureen Spencer, M.Ed, RN, CIC, FAPIC
Infection Prevention
Mayumi Verona, BSN, RN, CNOR
Dignity Health
Management
Paul Vajgrt
CEO
Andrew Morgan R.Ph.
Executive Vice President,
Regulatory Affairs
and Clinical
Alex M. Kasper
Chief Financial Officer